8月5日，西维斯健康盘中下跌9.74%，报94.25美元/股，成交额9718.15万美元。尽管公司二季度业绩大超预期，调整后每股收益2.58美元远超市场预期的1.85美元，营收1061亿美元同比增长7.3%，并将全年调整后EPS指引上调至7.90-8.10美元，但盘中股价急转直下。
消息面上，一位高管在财报电话会议前坦言，预计340B药品折扣计划带来的市场压力将在明年持续发酵，对药房服务业务构成显著拖累。同时，公司重申对年内剩余时间的谨慎立场，表示成本趋势持续攀升叠加宏观经济逆风，核心业务增长或将受到抑制。中长期盈利前景的不确定性完全盖过了短期业绩超预期的积极影响。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.